Mark Stetter Acquires Shares of Zoetis Inc. (ZTS)

Mark Stetter recently purchased 318 shares of Zoetis Inc. (NYSE: ZTS) at a price of $78.71 each, totaling $25,029.78. This transaction took place on June 18, 2026, and was not part of a pre-arranged trading plan.

Insider Buying and Selling at Zoetis Inc.

Mark Stetter's recent purchase of 318 shares on June 18, 2026, adds to his previous trading activity with Zoetis. Earlier, on May 21, 2026, he bought 1,572 shares and sold the same amount on the same day. Additionally, Michael McCallister sold 1,209 shares on June 10, 2026, and Louise Parent sold a total of 12,131 shares across two transactions on May 20, 2026.

Other Institutional Activity in Zoetis Inc.

In recent institutional moves, BlackRock, Inc. reduced its holdings by 1,766,511 shares, now holding 35,584,312 shares valued at about $4.21 billion, a 4.7% decrease. Vanguard Capital Management LLC opened a new position with 26,072,846 shares worth around $3.08 billion. Similarly, Vanguard Portfolio Management LLC also initiated a stake with 23,967,400 shares valued at approximately $2.83 billion. Meanwhile, State Street Corp trimmed its position by 472,490 shares, holding 19,324,401 shares valued at $2.28 billion, reflecting a 2.4% decrease.

Zoetis Inc. Stock Down 1.9%

Shares of Zoetis Inc. traded at $78.71 on Tuesday. The company, with a market cap of approximately $31.8 billion, has a P/E ratio of 12.44 and a forward P/E of 10.22. Its beta stands at 0.741, indicating lower volatility compared to the market. The stock's 52-week range is between $72.38 and $161.77, with a 50-day moving average of $94.33 and a 200-day moving average of $120.72. Zoetis maintains a current ratio of 3.15 and a quick ratio of 1.68, with a debt-to-equity ratio of 286.24.

Recent Earnings

Zoetis Inc. reported revenue of approximately $9.53 billion, reflecting a growth rate of 2.9%. The company achieved a net margin of 28.04% and a return on equity of 67.75%. Its earnings per share stood at $6.10. The next earnings report is expected on August 4, 2026.

Dividend

Zoetis Inc. offers an annual dividend rate of $2.12 per share, resulting in a yield of 2.69%. The dividend payout ratio is 33.28%.

Analysts Set New Price Targets

On May 22, 2026, Stifel maintained a hold rating on Zoetis with a price target of $95. Citigroup upheld a buy rating with a $112 target on May 18, 2026. UBS, on May 8, 2026, maintained a hold rating with a target of $99, while JP Morgan affirmed a buy rating with a $130 target. Overall, analysts hold a consensus buy recommendation with an average target price of $124.59 based on 17 opinions.

About Zoetis Inc.

Zoetis Inc. is a global leader in animal health, engaged in the discovery, development, manufacture, and sale of medicines and vaccines for pets and livestock. Headquartered in Parsippany, New Jersey, the company serves veterinarians, livestock producers, and pet owners. It offers products across various categories, including parasiticides, vaccines, and diagnostics. Led by CEO Kristin C. Peck, Zoetis employs approximately 14,500 people worldwide.

Bottom Line

Mark Stetter's recent purchase of Zoetis shares highlights ongoing insider interest in the company. Zoetis is a major player in the animal health sector, with robust financial performance and a strong market presence. Investors keeping track of insider and institutional activities should note these developments, though it's important to remember that insider transactions are often part of broader personal financial strategies.